Seasonal Influenza: Epidemiology Forecast in Asia-Pacific Markets to 2028

2019-12-31
Price :
Published : Dec-2019
No. of Pages : 30

Seasonal Influenza: Epidemiology Forecast in Asia-Pacific Markets to 2028

Summary

Seasonal influenza is a contagious respiratory viral illness. There are four types of seasonal influenza viruses (A, B, C, and D); however, only types A and B cause human disease of public health concern. Influenza transmission occurs when people with flu cough, sneeze, or talk and disseminate droplets. These droplets can land in the mouths or noses of people who then inhale them into the lungs. GlobalData epidemiologists identified country-specific population-based studies published in peer-reviewed journal articles and government-collated surveillance data to build the influenza forecast, and utilized appropriate proxy data where applicable.

In 2018, there were 18,518,017 cases of lab-confirmed seasonal influenza in the 3GM combined. India had the most cases among the 3GM with 9,561,398 cases, followed by China with 7,611,389 cases. By 2028, the 3GM will have very little change in incident cases of lab-confirmed seasonal influenza, with 18,578,681 cases, at an Annual Growth Rate (AGR) of 0.03%.

Vaccination is an effective way to prevent influenza in the youngest population, as vaccine effectiveness is the strongest in younger populations. However, vaccination rates in China and India remain extremely low, at around 1-2% in the general population. In Japan, vaccination is better, at 29% in 2018 for the general population and 40% for ages 0-4 years. However, vaccination rates in Japan are low compared with Western markets, such as the US, where up to 70% of children ages 0-4 years are vaccinated.

Scope

– The Seasonal Influenza in Asia-Pacific Markets Epidemiology Report provides an overview of the risk factors and global trends of seasonal influenza in the three Asia-Pacific growth markets (3GM: China, India, and Japan).
– This report also includes a 10-year epidemiological forecast for the following segmentations in all ages across the 3GM: the diagnosed incident cases of lab-confirmed seasonal influenza, lab-confirmed seasonal influenza mortality, and vaccination rates for seasonal influenza.
– The seasonal influenza epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
– The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 3GM.

Reasons to buy

The Seasonal Influenza Epidemiology series will allow you to –
– Develop business strategies by understanding the trends shaping and driving the Asia-Pacific seasonal influenza market.
– Quantify patient populations in the global seasonal influenza market to improve product design, pricing, and launch plans.
– Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for seasonal influenza vaccines in each of the markets covered.
– Understand magnitude of lab-confirmed seasonal influenza mortality and the population receiving seasonal influenza vaccination.

Filed in: Pharmaceutical, Therapeutics
Publisher : GlobalData
More Reports
Title Price Buy Now

Telehealth Market by Component Software & Services (RPM, RTM), Application (Teleradiology, telestroke, teleICU), Hardware (Glucose Meters), End-User (Provider, Payer, Patient), Delivery Mode (On-Premise, Cloud) Trends & Global Forecast to 2025

“The telehealth market is projected to grow at a CAGR of 16.9% during the forecast period (2020–2025).” The global telehealth market is projected to reach USD 55.6 billion by 2025 from USD 25.5 billion in 2020, at a CAGR of 16.9 % during the forecast period. The key factors driving the growth of this market include the need to expand healthcare access, the growing prevalence of chronic diseases and conditions, a shortage of physicians, advancements in telecommunications, and government support and raising awareness. However, regional variations in regulations, fraud, and the use of social media for care providers will restrict the market growth during the forecast period. “The software & services segment will grow at the highest rate during the forecast period.” Base......
$4950

Biosimilars Market by Product (Insulin, Interferon, Etanercept, Infliximab, Rituximab, Glucagon, Calcitonin), Manufacturing (In-house, Contract) & Indication (Oncology, Chronic Disease, Blood Disorder, Autoimmune Disease), Region – Global Forecast to 2025

“The global biosimilars  market size is projected to register a CAGR of 24.7% during the forecast period.” The global biosimilars market size is projected to reach USD 35.7 billion by 2025 from USD 11.8 billion in 2020, at a CAGR of 24.7%. Growth in this industry is driven by the rising incidence of chronic diseases and the increasing demand for biosimilars due to their cost-effectiveness. On the other hand, complexities in manufacturing restraining the market. “The monoclonal antibody segment is anticipated to grow at the fastest growth rate during the forecast period.” The biosimilars market by service is categorized into insulin, monoclonal antibodies, recombinant human growth hormone (rhGH), granulocyte colony-stimulating factor, interferon, erythropoietin, etanercept......
$5650

Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H1, 2020

Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H1, 2020 Summary GlobalData's clinical trial report, "Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H1, 2020" provides an overview of Non-Alcoholic Steatohepatitis (NASH) Clinical trials scenario. This report provides top line data relating to the clinical trials on Non-Alcoholic Steatohepatitis (NASH). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generate......
$2500

Pre-Diabetes Impaired Glucose Tolerance Global Clinical Trials Review, H1, 2020

Pre-Diabetes Impaired Glucose Tolerance Global Clinical Trials Review, H1, 2020 Summary GlobalData's clinical trial report, "Pre-Diabetes Impaired Glucose Tolerance Global Clinical Trials Review, H1, 2020" provides an overview of Pre-Diabetes Impaired Glucose Tolerance Clinical trials scenario. This report provides top line data relating to the clinical trials on Pre-Diabetes Impaired Glucose Tolerance. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports ......
$2500

Schizoaffective Disorder Global Clinical Trials Review, H1, 2020

Schizoaffective Disorder Global Clinical Trials Review, H1, 2020 Summary GlobalData's clinical trial report, "Schizoaffective Disorder Global Clinical Trials Review, H1, 2020" provides an overview of Schizoaffective Disorder Clinical trials scenario. This report provides top line data relating to the clinical trials on Schizoaffective Disorder. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Phar......
$2500

Nasopharyngeal Cancer Global Clinical Trials Review, H1, 2020

Nasopharyngeal Cancer Global Clinical Trials Review, H1, 2020 Summary GlobalData's clinical trial report, "Nasopharyngeal Cancer Global Clinical Trials Review, H1, 2020" provides an overview of Nasopharyngeal Cancer Clinical trials scenario. This report provides top line data relating to the clinical trials on Nasopharyngeal Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Cl......
$2500

Post Operative Nausea And Vomiting Global Clinical Trials Review, H1, 2020

Post Operative Nausea And Vomiting Global Clinical Trials Review, H1, 2020 Summary GlobalData's clinical trial report, "Post Operative Nausea And Vomiting Global Clinical Trials Review, H1, 2020" provides an overview of Post Operative Nausea And Vomiting Clinical trials scenario. This report provides top line data relating to the clinical trials on Post Operative Nausea And Vomiting. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using ......
$2500

Seasonal Allergic Rhinitis Global Clinical Trials Review, H1, 2020

Seasonal Allergic Rhinitis Global Clinical Trials Review, H1, 2020 Summary GlobalData's clinical trial report, "Seasonal Allergic Rhinitis Global Clinical Trials Review, H1, 2020" provides an overview of Seasonal Allergic Rhinitis Clinical trials scenario. This report provides top line data relating to the clinical trials on Seasonal Allergic Rhinitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary databas......
$2500

Chemotherapy Induced Nausea and Vomiting Global Clinical Trials Review, H1, 2020

Chemotherapy Induced Nausea and Vomiting Global Clinical Trials Review, H1, 2020 Summary GlobalData's clinical trial report, "Chemotherapy Induced Nausea and Vomiting Global Clinical Trials Review, H1, 2020" provides an overview of Chemotherapy Induced Nausea and Vomiting Clinical trials scenario. This report provides top line data relating to the clinical trials on Chemotherapy Induced Nausea and Vomiting. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Repo......
$2500

Cirrhosis Global Clinical Trials Review, H1, 2020

Cirrhosis Global Clinical Trials Review, H1, 2020 Summary GlobalData's clinical trial report, "Cirrhosis Global Clinical Trials Review, H1, 2020" provides an overview of Cirrhosis Clinical trials scenario. This report provides top line data relating to the clinical trials on Cirrhosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are coll......
$2500
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy